查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球血液肿瘤学检测市场：按产品/服务（服务,检测试剂盒）,癌症（白血病（急性髓系,急性淋巴细胞）,淋巴瘤,技术（PCR,NGS）,END预测用户至2027
市场调查报告书
商品编码
1162477

全球血液肿瘤学检测市场：按产品/服务（服务,检测试剂盒）,癌症（白血病（急性髓系,急性淋巴细胞）,淋巴瘤,技术（PCR,NGS）,END预测用户至2027

Hemato Oncology Testing Market by Product & Services (Services, Assay Kits), Cancer (Leukemia (Acute Myeloid, Acute Lymphocytic), Lymphoma (Non-Hodgkin, Hodgkin), Technology (PCR, NGS), End User - Global Forecast to 2027
出版日期: | 出版商: MarketsandMarkets | 英文 141 Pages | 订单完成后即时交付

价格
简介目录

全球血液肿瘤检测市场规模预计将从 2022 年的 29 亿美元增长到 2027 年的 56 亿美元，复合年增长率为 14.2%。

这个市场的增长归因于血癌发病率的增加、研究合作的增加、个性化医疗会议的增加等。

“按产品/服务类型划分，服务业在预测期内的增长率最高”

到 2021 年，服务领域将占据全球血液学和肿瘤学检测市场的最大份额。这可以归因于血癌发病率的显着增加。因此，患者需要在治疗期间进行持续监测和检测，越来越多的公司对血液肿瘤进行临床试验，这需要血液肿瘤检测产品和诊断检测程序的诊断。中心的增加预计将推动对服务领域的需求血液肿瘤产品市场。

“在预测期内，淋巴瘤将占癌症类型最高的复合年增长率”

2021 年，淋巴瘤领域将主导全球市场。这是由于淋巴瘤患病率上升和世界人口老龄化加剧等因素导致淋巴瘤发病率上升。

“从技术类型来看，PCR领域占比最高”

2021 年，PCR 部分主导了血液肿瘤检测市场。这部分是由于该技术因其易于使用和检测试剂盒的可用性而得到广泛使用。

“亚太地区在预测期内将以最高复合年增长率增长”

预计亚太地区血液肿瘤检测市场在预测期内将实现高速增长。推动市场增长的因素包括人口老龄化、对优质医疗服务的需求不断增加以及行业对癌症生物标誌物的兴趣日益浓厚。

本报告按产品/服务、癌症类型、技术和最终用户分析了全球血液学和肿瘤学市场，包括市场的基本结构和最新发展、主要市场驱动因素和製约因素。我们正在调查按区域和区域划分的市场趋势前景，市场竞争状况以及主要公司的概况。

内容

第一章介绍

第二章研究方法论

第 3 章执行摘要

第 4 章重要注意事项

第 5 章市场概述

  • 介绍
  • 市场动态
    • 司机
    • 约束因素
    • 机会
    • 任务

第 6 章血液肿瘤检测市场，按产品/服务分类

  • 介绍
  • 服务
  • 检测试剂盒

第 7 章血液肿瘤检测市场：按癌症类型分类

  • 介绍
  • 白血病
    • 急性髓性白血病
    • 急性淋巴细胞白血病
    • 其他白血病
  • 淋巴瘤
    • 非霍奇金淋巴瘤
    • 霍奇金淋巴瘤
  • 其他癌症

第 8 章血液肿瘤检测市场：按技术分类

  • 介绍
  • PCR（聚合□炼式反应）
  • IHC（免疫组织化学染色）
  • NGS（下一代测序）
  • 细胞遗传学
  • 其他技术

第 9 章血液肿瘤检测市场：按最终用户分类

  • 介绍
  • 临床实验室
  • 医院
  • 教育和研究机构
  • 其他最终用户

第 10 章血液肿瘤市场：按地区

  • 介绍
  • 北美
    • 美国
    • 加拿大
  • 欧洲
  • 亚太地区
  • 其他国家（行）

第11章竞争格局

  • 概览
  • 主要公司/有影响力的公司采用的战略
  • 市场份额分析（2021 年）
  • 公司评估矩阵
  • 关键策略
    • 产品发布
    • 资本交易
    • 其他趋势

第12章公司简介

  • 主要公司
    • ABBOTT LABORATORIES
    • F. HOFFMANN-LA ROCHE AG
    • QIAGEN N.V.
    • THERMO FISHER SCIENTIFIC, INC.
    • ILLUMINA, INC.
    • BIO-RAD LABORATORIES, INC.
    • MOLECULARMD (ICON PLC子会社)
    • ADAPTIVE BIOTECHNOLOGIES
    • ARCHERDX, INC. (INVITAE CORPORATION子会社)
    • ARUP LABORATORIES, INC.
    • ASURAGEN, INC.
    • INVIVOSCRIBE, INC.
    • AMOY DIAGNOSTICS CO., LTD.
    • ELITECHGROUP
    • VELA DIAGNOSTICS
  • 其他企业
    • GENTRONIX LIMITED
    • BIOIVT
    • SAGA DIAGNOSTICS
    • OLINK
    • CANCER DIAGNOSTICS, INC.

第13章 附录

简介目录
Product Code: MD 7180

The global Hemato oncology testing market is projected to reach USD 5.6 billion by 2027 from an estimated USD 2.9 Billion in 2022, at a CAGR of 14.2%. The growth in this market is attributed to the growing incidence of hematologic cancer, increasing collaborations, and the increasing number of conferences on personalized medicine.

"The Services segment accounted for the highest growth rate in the Hemato oncology testing market, by product and services type, during the forecast period"

On the basis of products & services type, the global hemato oncology testing market is segmented into services and assay kits.

In 2021, The services segment accounted for the largest share of the global hemato oncology testing market in 2021. This can be attributed to the increase in the number of hematologic cancer significantly. Hence the the patient needs continuous monitoring and testing during the treatment, the increasing collaration between the companies for conducting the clinical trails on the hematologic cancers requires the hemato oncology testing products and the raising number of the diagonostic centers for diagonotic testing procudures is expected to boost the demand for the the services segment in the hemato oncology testing product market .

"Lymphoma segment accounted for the highest CAGR by cancer type, during the forecast period"

By cancer type, the global leukemia, lymphoma, and other cancers market. In 2021, the lymphoma segment dominated the global market. This can be attributed to factor such as the increasing prevalence lymphoma and the risisng geriatric population across sthe globe is supporting the increasing incidence of the lymphoma cases which is a major driving factor for this market.

"The PCR segment accounted for the highest growth rate in the Hemato oncology testing market, by technology type, during the forecast period"

Based on type, the Hemato oncology testing market technology is segmented into PCR, IHC, NGS, cytogenetics, and other technologies.

In 2021, the PCR segment dominated hemato oncology testing market. Factors supporting the growth of the segment is the wide use of this technology owing to its ease of use and easy availability of assay kits.

"The Asia-Pacific market is expected to grow at the highest CAGR during the forecast period."

The Hemato oncology testing market is segmented into - North America, Europe, the Asia Pacific and ROW. The Hemato oncology testing market in several Asia-Pacific countries is expected to witness high growth during the forecast period. Market growth will be driven by the rising geriatric population, increasing demand for quality healthcare, and the growing focus on cancer biomarkers by various stakeholders in their respective healthcare systems.

A breakdown of the primary participants referred to for this report is provided below:

  • By Company Type: Tier 1-45%, Tier 2-35%, and Tier 3- 45%
  • By Designation: C-level-32%, Director-level-20%, and Others-48%
  • By Region: North America-35%, Europe-28%, Asia Pacific-25%, ROW¬-12%

Lists of Companies Profiled in the Report:

  • Abbott Laboratories (US)
  • F. Hoffman-La Roche (Switzerland)
  • QIAGEN (Germany)
  • Thermo Fisher Scientific (US)
  • Illumina (US)
  • Bio-Rad Laboratories (US)q
  • MolecularMD (Ireland)
  • ArcherDX (US)
  • ARUP Laboratories (US)
  • Asuragen (US)
  • Invivoscribe (US)
  • Adaptive Biotechnologies (US)
  • Amoy Diagnostics (China)
  • ELITechGroup (France)
  • Vela Diagnostics (Singapore)
  • Gentronix (UK)
  • BioIVT (US)
  • SAGA Diagnostics (Sweden)
  • Olink (Sweden)
  • Cancer Diagnostics (US)

Research Coverage

This report studies the Hemato oncology testing market based on the type of product, cancer, technology and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth. It analyzes the opportunities and challenges in the market and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five main regions (and the respective countries in these regions.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall Hemato oncology testing market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities and challenges.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS & EXCLUSIONS
  • 1.3 STUDY SCOPE
    • FIGURE 1 MARKETS COVERED
    • 1.3.1 REGIONAL SCOPE
    • 1.3.2 YEARS CONSIDERED
  • 1.4 CURRENCY CONSIDERED
  • 1.5 LIMITATIONS
  • 1.6 MARKET STAKEHOLDERS
  • 1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 2 RESEARCH DESIGN
  • 2.2 SECONDARY DATA
    • 2.2.1 SECONDARY SOURCES
    • 2.2.2 KEY DATA FROM SECONDARY SOURCES
  • 2.3 PRIMARY DATA
    • FIGURE 3 PRIMARY SOURCES
    • 2.3.1 KEY DATA FROM PRIMARY SOURCES
    • 2.3.2 KEY INDUSTRY INSIGHTS
  • 2.4 BREAKDOWN OF PRIMARY INTERVIEWS
    • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS
    • FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • 2.5 MARKET SIZE ESTIMATION
    • FIGURE 6 HEMATO-ONCOLOGY TESTING MARKET: BOTTOM-UP APPROACH
    • 2.5.1 GROWTH FORECAST
    • FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
    • 2.5.2 TOP-DOWN APPROACH
    • FIGURE 8 HEMATO-ONCOLOGY TESTING MARKET: TOP-DOWN APPROACH
  • 2.6 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 9 DATA TRIANGULATION METHODOLOGY
  • 2.7 RESEARCH ASSUMPTIONS
  • 2.8 STUDY ASSUMPTIONS
  • 2.9 INDICATORS AND OTHER ASSUMPTIONS
  • 2.10 RISK ASSESSMENT
    • TABLE 1 RISK ASSESSMENT
  • 2.11 RESEARCH LIMITATIONS

3 EXECUTIVE SUMMARY

    • FIGURE 10 HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2022 VS. 2027 (USD MILLION)
    • FIGURE 11 HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2022 VS. 2027 (USD MILLION)
    • FIGURE 12 HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION)
    • FIGURE 13 HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
    • FIGURE 14 HEMATO-ONCOLOGY TESTING MARKET, BY REGION, 2022 VS. 2027 (USD MILLION)

4 PREMIUM INSIGHTS

  • 4.1 HEMATO-ONCOLOGY TESTING MARKET OVERVIEW
    • FIGURE 15 GROWING INCIDENCE OF HEMATOLOGIC CANCERS TO DRIVE MARKET GROWTH
  • 4.2 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE (2021)
    • FIGURE 16 HEMATO-ONCOLOGY TESTING SERVICES DOMINATED NORTH AMERICAN MARKET IN 2021
  • 4.3 GEOGRAPHICAL SNAPSHOT OF HEMATO-ONCOLOGY TESTING MARKET
    • FIGURE 17 NORTH AMERICA ACCOUNTED FOR LARGEST MARKET SHARE IN 2021

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 18 HEMATO-ONCOLOGY TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Growing incidence of hematologic cancer
    • TABLE 1 GLOBAL HEMATOLOGIC CANCER INCIDENCE, BY TYPE, 2020-2040
    • TABLE 2 GLOBAL GERIATRIC POPULATION, BY REGION, 2019 VS. 2030
      • 5.2.1.2 Increasing collaborations between companies
      • 5.2.1.3 Rising number of private diagnostic centers
      • 5.2.1.4 Increasing conferences on personalized medicine
    • TABLE 3 HEMATO-ONCOLOGY TESTING MARKET: DETAILED LIST OF CONFERENCES AND EVENTS, 2022-2023
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Unfavorable reimbursement scenario
    • TABLE 4 REIMBURSEMENT SCENARIO FOR HEMATO-ONCOLOGY TESTING PRODUCTS ACROSS REGIONS
      • 5.2.2.2 Complex regulatory frameworks delaying approval of new molecular diagnostic tests
      • 5.2.2.3 High capital investments and low cost-benefit ratio for biomarkers
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Emerging markets
    • TABLE 5 CAPITAL HEALTH EXPENDITURE, BY COUNTRY, 2019
    • TABLE 6 INCIDENCE OF HEMATOLOGIC CANCERS, BY COUNTRY, 2020 VS. 2040
      • 5.2.3.2 Drug diagnostics co-development
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Intellectual property rights protection issues
      • 5.2.4.2 Shortage of trained professionals

6 HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE

  • 6.1 INTRODUCTION
    • TABLE 7 HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
  • 6.2 SERVICES
    • 6.2.1 RISING INCIDENCE OF HEMATOLOGIC CANCERS TO INCREASE DEMAND FOR HEMATO-ONCOLOGY SERVICES
    • TABLE 8 HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 9 HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY TYPE, 2020-2027 (USD MILLION)
  • 6.3 ASSAY KITS
    • 6.3.1 GROWING FOCUS ON DEVELOPMENT OF ADVANCED ASSAY KITS TO DRIVE GROWTH
    • TABLE 10 HEMATO-ONCOLOGY TESTING ASSAY KITS MARKET, BY REGION, 2020-2027 (USD MILLION)

7 HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE

  • 7.1 INTRODUCTION
    • TABLE 11 HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2020-2027 (USD MILLION)
  • 7.2 LEUKEMIA
    • FIGURE 19 GLOBAL LEUKEMIA INCIDENCE, 2020
    • TABLE 12 HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 13 HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE, 2020-2027 (USD MILLION)
    • 7.2.1 ACUTE MYELOID LEUKEMIA
      • 7.2.1.1 High incidence of AML in adults to drive growth
    • TABLE 14 HEMATO-ONCOLOGY TESTING MARKET FOR ACUTE MYELOID LEUKEMIA, BY REGION, 2020-2027 (USD MILLION)
    • 7.2.2 ACUTE LYMPHOCYTIC LEUKEMIA
      • 7.2.2.1 High incidence of ALL in children to support growth
    • TABLE 15 HEMATO-ONCOLOGY TESTING MARKET FOR ACUTE LYMPHOCYTIC LEUKEMIA, BY REGION, 2020-2027 (USD MILLION)
    • 7.2.3 OTHER LEUKEMIAS
    • TABLE 16 HEMATO-ONCOLOGY TESTING MARKET FOR OTHER LEUKEMIAS, BY REGION, 2020-2027 (USD MILLION)
  • 7.3 LYMPHOMA
    • TABLE 17 HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 18 HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE, 2020-2027 (USD MILLION)
    • 7.3.1 NON-HODGKIN LYMPHOMA
      • 7.3.1.1 Non-Hodgkin lymphoma to dominate market during forecast period
    • FIGURE 20 GLOBAL INCIDENCE OF NON-HODGKIN LYMPHOMA, 2020
    • TABLE 19 HEMATO-ONCOLOGY TESTING MARKET FOR NON-HODGKIN LYMPHOMA, BY REGION, 2020-2027 (USD MILLION)
    • 7.3.2 HODGKIN LYMPHOMA
      • 7.3.2.1 APAC hemato-oncology testing market for Hodgkin lymphoma to grow at highest rate
    • FIGURE 21 GLOBAL INCIDENCE OF HODGKIN LYMPHOMA, 2020
    • TABLE 20 HEMATO-ONCOLOGY TESTING MARKET FOR HODGKIN LYMPHOMA, BY REGION, 2020-2027 (USD MILLION)
  • 7.4 OTHER CANCERS
    • TABLE 21 HEMATO-ONCOLOGY TESTING MARKET FOR OTHER CANCERS, BY REGION, 2020-2027 (USD MILLION)

8 HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY

  • 8.1 INTRODUCTION
    • TABLE 22 HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
  • 8.2 PCR
    • 8.2.1 PCR TECHNOLOGY TO DOMINATE HEMATO-ONCOLOGY TESTING MARKET
    • TABLE 23 HEMATO-ONCOLOGY TESTING MARKET FOR PCR, BY REGION, 2020-2027 (USD MILLION)
  • 8.3 IHC
    • 8.3.1 ABILITY TO VISUALIZE TARGETED COMPONENTS IN SAMPLES TO BOOST ADOPTION
    • TABLE 24 HEMATO-ONCOLOGY TESTING MARKET FOR IHC, BY REGION, 2020-2027 (USD MILLION)
  • 8.4 NGS
    • 8.4.1 NGS SEGMENT TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
    • TABLE 25 HEMATO-ONCOLOGY TESTING MARKET FOR NGS, BY REGION, 2020-2027 (USD MILLION)
  • 8.5 CYTOGENETICS
    • 8.5.1 HEAVY DEPENDENCE ON CYTOGENETIC ANALYSIS FOR DIAGNOSIS OF LEUKEMIA AND LYMPHOMA TO FUEL GROWTH
    • TABLE 26 HEMATO-ONCOLOGY TESTING MARKET FOR CYTOGENETICS, BY REGION, 2020-2027 (USD MILLION)
  • 8.6 OTHER TECHNOLOGIES
    • TABLE 27 HEMATO-ONCOLOGY TESTING MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2020-2027 (USD MILLION)

9 HEMATO-ONCOLOGY TESTING MARKET, BY END USER

  • 9.1 INTRODUCTION
    • TABLE 28 HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 9.2 CLINICAL LABORATORIES
    • 9.2.1 PRESENCE OF ADVANCED INFRASTRUCTURE TO DRIVE MARKET
    • TABLE 29 HEMATO-ONCOLOGY TESTING MARKET FOR CLINICAL LABORATORIES, BY REGION, 2020-2027 (USD MILLION)
  • 9.3 HOSPITALS
    • 9.3.1 HIGH PATIENT FOOTFALL TO SUPPORT GROWTH
    • TABLE 30 HEMATO-ONCOLOGY TESTING MARKET FOR HOSPITALS, BY REGION, 2020-2027 (USD MILLION)
  • 9.4 ACADEMIC & RESEARCH INSTITUTES
    • 9.4.1 GROWING MEDICAL RESEARCH AND DRUG DEVELOPMENT IN ACADEMIC & RESEARCH INSTITUTES TO FUEL GROWTH
    • TABLE 31 HEMATO-ONCOLOGY TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2020-2027 (USD MILLION)
  • 9.5 OTHER END USERS
    • TABLE 32 HEMATO-ONCOLOGY TESTING MARKET FOR OTHER END USERS, BY REGION, 2020-2027 (USD MILLION)

10 HEMATO-ONCOLOGY TESTING MARKET, BY REGION

  • 10.1 INTRODUCTION
    • TABLE 33 HEMATO-ONCOLOGY TESTING MARKET, BY REGION, 2020-2027 (USD MILLION)
  • 10.2 NORTH AMERICA
    • FIGURE 22 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET SNAPSHOT
    • TABLE 34 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 35 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 36 NORTH AMERICA: HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 37 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2020-2027 (USD MILLION)
    • TABLE 38 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 39 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 40 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 41 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 10.2.1 US
      • 10.2.1.1 US to dominate North American hemato-oncology testing market during forecast period
    • TABLE 42 US: LEUKEMIA AT A GLANCE
    • TABLE 43 US: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 44 US: HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 45 US: HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2020-2027 (USD MILLION)
    • TABLE 46 US: HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 47 US: HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 48 US: HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 49 US: HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 10.2.2 CANADA
      • 10.2.2.1 Initiatives undertaken by healthcare authorities to support growth of market
    • TABLE 50 CANADA: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 51 CANADA: HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 52 CANADA: HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2020-2027 (USD MILLION)
    • TABLE 53 CANADA: HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 54 CANADA: HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 55 CANADA: HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 56 CANADA: HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 10.3 EUROPE
    • 10.3.1 RISING FOCUS ON BIOMARKER DEVELOPMENT IN EU COUNTRIES TO SUPPORT MARKET
    • TABLE 57 EUROPE: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 58 EUROPE: HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2020-2027 (USD MILLION)
    • TABLE 59 EUROPE: HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 60 EUROPE: HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 61 EUROPE: HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 62 EUROPE: HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 63 EUROPE: HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 10.4 ASIA PACIFIC
    • 10.4.1 ASIA PACIFIC MARKET TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
    • FIGURE 23 ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET SNAPSHOT
    • TABLE 64 ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 65 ASIA PACIFIC: HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 66 ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2020-2027 (USD MILLION)
    • TABLE 67 ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 68 ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 69 ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 70 ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 10.5 REST OF THE WORLD
    • TABLE 71 REST OF THE WORLD: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 72 REST OF THE WORLD: HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 73 REST OF THE WORLD: HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2020-2027 (USD MILLION)
    • TABLE 74 REST OF THE WORLD: HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 75 REST OF THE WORLD: HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 76 REST OF THE WORLD: HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 77 REST OF THE WORLD: HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)

11 COMPETITIVE LANDSCAPE

  • 11.1 OVERVIEW
  • 11.2 STRATEGIES ADOPTED BY KEY PLAYERS/RIGHT TO WIN
    • TABLE 78 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN HEMATO-ONCOLOGY TESTING MARKET
  • 11.3 MARKET SHARE ANALYSIS, 2021
    • TABLE 79 HEMATO-ONCOLOGY TESTING MARKET: DEGREE OF COMPETITION
  • 11.4 COMPANY EVALUATION MATRIX
    • 11.4.1 STARS
    • 11.4.2 EMERGING LEADERS
    • 11.4.3 PERVASIVE PLAYERS
    • 11.4.4 PARTICIPANTS
    • FIGURE 24 HEMATO-ONCOLOGY TESTING MARKET: COMPETITIVE LEADERSHIP MAPPING (2021)
  • 11.5 KEY STRATEGIES
    • 11.5.1 PRODUCT LAUNCHES
    • TABLE 80 KEY PRODUCT LAUNCHES, JANUARY 2019-NOVEMBER 2022
    • 11.5.2 DEALS
    • TABLE 81 KEY DEALS, JANUARY 2019-AUGUST 2022
    • 11.5.3 OTHER DEVELOPMENTS
    • TABLE 82 OTHER KEY DEVELOPMENTS, JANUARY 2019-NOVEMBER 2022

12 COMPANY PROFILES

  • 12.1 KEY PLAYERS
  • (Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))**
    • 12.1.1 ABBOTT LABORATORIES
    • TABLE 83 ABBOTT LABORATORIES: BUSINESS OVERVIEW
    • FIGURE 25 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2021)
    • 12.1.2 F. HOFFMANN-LA ROCHE AG
    • TABLE 84 F. HOFFMANN-LA ROCHE AG: BUSINESS OVERVIEW
    • FIGURE 26 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2021)
    • 12.1.3 QIAGEN N.V.
    • TABLE 85 QIAGEN N.V.: BUSINESS OVERVIEW
    • FIGURE 27 QIAGEN N.V.: COMPANY SNAPSHOT (2021)
    • 12.1.4 THERMO FISHER SCIENTIFIC, INC.
    • TABLE 86 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
    • FIGURE 28 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2021)
    • 12.1.5 ILLUMINA, INC.
    • TABLE 87 ILLUMINA, INC.: BUSINESS OVERVIEW
    • FIGURE 29 ILLUMINA, INC.: COMPANY SNAPSHOT (2021)
    • 12.1.6 BIO-RAD LABORATORIES, INC.
    • TABLE 88 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
    • FIGURE 30 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2021)
    • 12.1.7 MOLECULARMD (A SUBSIDIARY OF ICON PLC)
    • TABLE 89 ICON PLC: BUSINESS OVERVIEW
    • FIGURE 31 ICON PLC: COMPANY SNAPSHOT (2021)
    • 12.1.8 ADAPTIVE BIOTECHNOLOGIES
    • TABLE 90 ADAPTIVE BIOTECHNOLOGIES: BUSINESS OVERVIEW
    • FIGURE 32 ADAPTIVE BIOTECHNOLOGIES: COMPANY SNAPSHOT (2021)
    • 12.1.9 ARCHERDX, INC. (A SUBSIDIARY OF INVITAE CORPORATION)
    • TABLE 91 ARCHERDX, INC.: BUSINESS OVERVIEW
    • 12.1.10 ARUP LABORATORIES, INC.
    • TABLE 92 ARUP LABORATORIES, INC.: BUSINESS OVERVIEW
    • 12.1.11 ASURAGEN, INC.
    • TABLE 93 ASURAGEN, INC.: BUSINESS OVERVIEW
    • 12.1.12 INVIVOSCRIBE, INC.
    • TABLE 94 INVIVOSCRIBE, INC.: BUSINESS OVERVIEW
    • 12.1.13 AMOY DIAGNOSTICS CO., LTD.
    • TABLE 95 AMOY DIAGNOSTICS CO., LTD.: BUSINESS OVERVIEW
    • 12.1.14 ELITECHGROUP
    • TABLE 96 ELITECHGROUP: BUSINESS OVERVIEW
    • 12.1.15 VELA DIAGNOSTICS
    • TABLE 97 VELA DIAGNOSTICS: BUSINESS OVERVIEW
  • 12.2 OTHER PLAYERS
    • 12.2.1 GENTRONIX LIMITED
    • 12.2.2 BIOIVT
    • 12.2.3 SAGA DIAGNOSTICS
    • 12.2.4 OLINK
    • 12.2.5 CANCER DIAGNOSTICS, INC.
  • *Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

13 APPENDIX

  • 13.1 DISCUSSION GUIDE
  • 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.3 CUSTOMIZATION OPTIONS
  • 13.4 RELATED REPORTS
  • 13.5 AUTHOR DETAILS